Table 2.

Characteristics of zinc-induced anemia in WD

Case source	Age	Zinc dose and course (Bold:high dose)	Chelator drug	HGB (g/dL)	Neutrophils (× 109/L)	Bone marrow	Treatment	Time to normal blood counts
Linn et al[10]	43 y	207 mg/d for 30y	No	Anemia	Neutropenia	Unknown	Zinc withdrawal	Unknown
Horvath et al[11]	40 y	200 mg/d for 14y and 250 mg/d for 1y	Initial Penicillamine for 6 m	7.8	0.26	Ring sideroblasts	Zinc withdrawal	Unknown
Dzieżyc et al. [12]	18 y	72.7 mg/d for 6y	No	10	0.17	MDS excluded	Zinc withdrawal	2 months
Rau et al. [13]	16 y	High dose for 9 m	Initial Penicillamine for 2y	5.8	Neutropenia	MDS, ring sideroblasts	Zinc withdrawal and copper supplement	8 weeks
Cortese et al. [14]	51 y	242 mg/d for 13y and 484 mg/d for 1y	No	6.5	0.25	MDS	Zinc dose reduction	Unknown
Foubert-Samier et al. [15]	43 y	142 mg/d for 25y	With Trientine 900 mg/d for 25y	10.6	0.94	Not performed	Zinc withdrawal	Unknown
Van den Hamer et al. [16]	56 y	484 mg/d for 2y	Initial Penicillamine for 29y	Anemia	Neutropenia	Unknown	Copper supplement	Unknown
Mohamed et al. [17]	26y	80.7 mg/d for 13y	No	7.4	0.2	vacuolated myeloid and erythroid precursors	Zinc withdrawal and copper supplement	4 months
Present case	11 y 4 m	240 mg/d for 4y4 m	No	40	0.08	MDS	Zinc withdrawal	4 months

Age: Age when presented with anemia, y years, m months, MDS Myelocytic dysplasia syndrome